VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

NCT02898753 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: VAL1221-201-16
• Study Type: interventional
• Target: 12
• Locations: 2 countries
• Sites: 3

Brief Summary

This Phase I/II open-label, randomized, dose-escalation study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VAL-1221 versus Myozyme®/Lumizyme® in participants with late-onset glycogen storage disease-II (GSD-II) (Pompe disease)

Conditions

Pompe Disease

Keywords

GSD-II; Pompe Disease; Glycogen Storage Diseases; GAA

Outcome Measures

Primary Outcomes (4)

• Number of Treatment-related Treatment-emergent Adverse Events (TEAEs)

  Baseline of Study Part 1 though Month 24 of Study Part 2

• Number of Participants With Infusion-Associated Reactions to VAL-1221

  Baseline of Study Part 1 though Month 24 of Study Part 2

• Percentage of Participants with Anti-VAL-1221 Antibodies

  Baseline of Study Part 1 though Month 24 of Study Part 2

• Percentage of Participants with GAA Antibodies

  Baseline of Study Part 1 though Month 24 of Study Part 2

Secondary Outcomes (11)

• Pharmacokinetics of VAL-1221 in Plasma: Maximum Observed Concentration (Cmax)

  Part 1: Pre-infusion, end of infusion (EOI) (infusion duration 1 mg/kg/hour), at 0.25, 0.5, 1, 2, 4, 12, 24, 48 and 336 hours after EOI on Days 1, 2, 3 and Week 12; Part 2: Pre-infusion on Weeks 12, 14, 16, 18, 20, 22, Months 12, 24, 36

• Pharmacokinetics of VAL-1221 in Plasma: Time to Reach Maximum Concentration (Tmax)

  Part 1: Pre-infusion, end of infusion (EOI) (infusion duration 1 mg/kg/hour), at 0.25, 0.5, 1, 2, 4, 12, 24, 48 and 336 hours after EOI on Days 1, 2, 3 and Week 12; Part 2: Pre-infusion on Weeks 12, 14, 16, 18, 20, 22, Months 12, 24, 36

• Pharmacokinetics of VAL-1221 in Plasma: Area Under the Concentration Time Curve (AUC)

  Part 1: Pre-infusion, end of infusion (EOI) (infusion duration 1 mg/kg/hour), at 0.25, 0.5, 1, 2, 4, 12, 24, 48 and 336 hours after EOI on Days 1, 2, 3 and Week 12; Part 2: Pre-infusion on Weeks 12, 14, 16, 18, 20, 22, Months 12, 24, 36

• Pharmacokinetics of VAL-1221 in Plasma: Terminal Elimination Half-Life ( t1/2)

  Part 1: Pre-infusion, end of infusion (EOI) (infusion duration 1 mg/kg/hour), at 0.25, 0.5, 1, 2, 4, 12, 24, 48 and 336 hours after EOI on Days 1, 2, 3 and Week 12; Part 2: Pre-infusion on Weeks 12, 14, 16, 18, 20, 22, Months 12, 24, 36

• Pharmacokinetics of VAL-1221 in Plasma: Apparent Total Body Clearance (CL)

  Part 1: Pre-infusion, end of infusion (EOI) (infusion duration 1 mg/kg/hour), at 0.25, 0.5, 1, 2, 4, 12, 24, 48 and 336 hours after EOI on Days 1, 2, 3 and Week 12; Part 2: Pre-infusion on Weeks 12, 14, 16, 18, 20, 22, Months 12, 24, 36

Study Arms (4)

VAL-1221 3 mg/kg

EXPERIMENTAL

Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions. Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data.

Drug: VAL-1221

VAL-1221 10 mg/kg

EXPERIMENTAL

Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions. Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data.

Drug: VAL-1221

VAL-1221 30 mg/kg

EXPERIMENTAL

Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions. Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week.

Drug: VAL-1221

rhGAA

ACTIVE COMPARATOR

Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme. Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week.

Drug: VAL-1221; Drug: RhGAA

Interventions

VAL-1221 DRUG

VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description

VAL-1221 10 mg/kg; VAL-1221 3 mg/kg; VAL-1221 30 mg/kg; rhGAA

RhGAA DRUG

Active comparator

Also known as: Myozyme, Lumizyme

rhGAA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant is able and willing to provide informed consent prior to any study procedures are performed
• Diagnosis of GSDII based on one of the following:
• Endogenous cultured skin fibroblast GAA activity less than (\<) 40 percent (%) of adult normal level
• Endogenous whole blood or dried blood spot GAA activity in deficiency range
• Genetic analysis showing pathogenic variants in both alleles
• Onset of Pompe disease-related symptoms after 1 year of age
• Previously treated with Myozyme or Lumizyme for at least 12 months and on a stable regimen for the past 6 months
• Sexually active participants who are willing to use an acceptable method of contraception (abstinence, oral contraceptives, barrier method with spermicide, surgical sterilization, implanted or injectable contraceptives with a stable dose for at least 1 month prior to Baseline, hormonal intra-uterine device \[IUD\] inserted at least 1 month prior to Baseline) during the study and for 30 days after completion of treatment
• If participant is female and not considered to be of childbearing potential, she is at least 2 years post-menopause, has undergone a tubal ligation, a total hysterectomy or bilateral oophorectomy
• If participant is female and of childbearing potential, she has a negative serum pregnancy test during screening and Baseline and must be willing to undergo pregnancy testing at specific intervals during the study
• Participant meets at least one of the following criteria: greater than (\>) 30% and \<80% predicted upright forced volume capacity (FVC) or participant is able to walk \>20% but \<80% predicted normal on 6-minute walk test with or without use of assistive devices
• Able to comply with protocol requirements

You may not qualify if:

• Cardiac involvement in first year of life
• Anti-GAA antibody titers \>1:51,200 at two time points
• Prior use of chaperone therapy for GSD-II within the last 12 months
• Use of immunosuppressive medication other than glucocorticoids within 6 months prior to study enrollment
• Use of invasive ventilatory assistance other than Bilevel Positive Airway Pressure (BiPAP) at night or during periods of rest
• Has received any investigational medication or has enrolled in any study involving investigational drugs or therapies within 30 days prior to first dose of study drug
• Start of or change in usual regimen of albuterol or respiratory muscle training within 30 days prior to first dose of study drug
• History of sensitivity to any of the constituents of the study drug
• Participant is breastfeeding or planning to become pregnant or to breastfeed during the study or is currently breastfeeding
• Participant has a medical condition or circumstance that, in the opinion of the investigator, might compromise the participant's ability to comply with the protocol or the participant's well-being or safety
• Participant has any condition that, in the view of the investigator, places the participant at high risk of poor treatment compliance or of not completing the study

Sponsors & Collaborators

• Valerion Therapeutics, LLC: lead

Study Sites (3)

University of California, Irvine

Orange, California, 92868, United States

Location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

National Hospital for Neurology and Neurosurgery

London, WC1N 3BG, United Kingdom

Location

MeSH Terms

Conditions

Glycogen Storage Disease Type II; Glycogen Storage Disease

Interventions

GAA protein, human

Condition Hierarchy (Ancestors)

Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Carbohydrate Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Hal Landy, MD

  Valerion Therapeutics, LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 8, 2016
• First Posted: September 13, 2016
• Study Start: June 21, 2017
• Primary Completion: March 25, 2020
• Study Completion: March 25, 2020
• Last Updated: June 2, 2020

Record last verified: 2020-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (2); GB (1)